Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates

Neurimmune AG is stepping out from behind the long shadow of its best-known therapeutic candidate – the amyloid-beta-targeting aducanumab for Alzheimer’s disease, which Biogen intends to submit for US Food and Drug Administration approval any day now. The Swiss company has begun to more prominently showcase its growing clinical pipeline and may seek external partners as later-stage programs achieve proof-of-concept to fund its ongoing drug discovery work.

Zurich-based Neurimmune, with just 50 employees, recently took its sixth antibody candidate into clinical trials, enrolling the first patient in a Phase I study of NI006 in the treatment of transthyretin amyloid cardiomyopathy (ATTR cardiomyopathy)